Vor Bio Reports $514.5M Pro-Forma Cash, Runway Into 2029; Phase 3 Data Expected 1H27
VOR has more than doubled off its 52-week low of $6.5.
Summary
Vor Bio's Q2 2026 results show a dramatically improved financial position versus the prior year, with a pro-forma cash balance of $514.5 million expected to fund operations into early 2029. This follows the 10-Q filed today disclosing a material weakness and going concern warning, making the cash runway update critical for assessing survival risk. R&D expenses dropped sharply to $25.9 million from $261.5 million in Q2 2025, reflecting the absence of the one-time telitacicept license payment. The company also confirmed enrollment is on track for the Phase 3 UPSTREAM MG trial in generalized myasthenia gravis, with topline data anticipated in the first half of 2027. The cash position and trial timelines provide concrete milestones for a stock that has faced significant governance and financial distress.
At the time of this announcement, VOR was trading at $22.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.50 to $50.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.